Search

Your search keyword '"Qi, Miao"' showing total 391 results

Search Constraints

Start Over You searched for: Author "Qi, Miao" Remove constraint Author: "Qi, Miao" Database OpenAIRE Remove constraint Database: OpenAIRE
391 results on '"Qi, Miao"'

Search Results

4. Repair versus replacement for active endocarditis of the mitral valve: 9 years of experience

5. Is Malignancies Related Gastrointestinal Bleeding Safe for Cardiopulmonary Bypass Surgery? - A Case-control Study

7. Reversible Myocardial Calcification Following Acute Heart Failure and Kidney Injury Caused by Valsalva Sinus Rupture

8. Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature

9. Prevalence, Genetic Background, and Clinical Phenotype of Congenital Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension

10. Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer

11. Non–open-heart surgery for intravascular leiomyomatosis extending from the inferior vena cava to the right heart chamber

12. Neurocognitive trajectories and their clinical implications in first-episode schizophrenia after one year of antipsychotic treatment

13. Outcomes of surgical treatment for active infective endocarditis under COVID‐19 pandemic

14. Mediating Role of Hope Between Social Support and Self-Management Among Chinese Liver Transplant Recipients: A Multi-Center Cross-Sectional Study

15. Giant coronary aneurysm of Behcet's disease with sudden syncope: a case report

16. Data from BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy

17. Supplementary Figure from BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy

18. circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway

19. Supplementary Table S1 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

20. Supplementary Figure S3 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

21. Supplementary Figure S8 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

22. Supplementary Figure S7 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

23. Supplementary Figure S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

24. Supplementary Figure S9 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

25. Supplementary Materials and Methods from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

26. Supplementary Figure S6 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

27. Supplementary Figure S5 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

28. Supplementary Table S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

29. Supplementary Figure S4 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

30. Supplementary Figure S1 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

31. Data from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

32. A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression

33. Differences in Cardiac Rupture and Hemopericardium Caused by Blunt Chest Injury, Acute Myocardial Infarct, Aortic Dissection and CPR

35. Racial Disparities in Quantitative MRI for African American and White Men with Prostate Cancer

36. A general photo-induced wide-scope regioselective hydroboration of alkenes without using a photocatalyst or an external initiator

37. Visible-light-induced 1,2-diphenyldisulfane-catalyzed regioselective hydroboration of electron-deficient alkenes

42. The immunological characteristics of TSPAN1 expressing B cells in autoimmune hepatitis

44. Optimizing Phosphorus Application for Winter Wheat Production in the Coastal Saline Area

45. Construction of nursing quality evaluation index system for kidney transplant patients: a Delphi method

47. No-Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial

48. Diatomite-based magnesium sulfate composites for thermochemical energy storage: Preparation and performance investigation

50. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database

Catalog

Books, media, physical & digital resources